Uncategorized
New Real-World Analysis of TEPEZZA® (teprotumumab-trbw) Use Indicates a Small Percentage of People Receive a Second Course of Treatment
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics announced new data on real-world TEPEZZA (teprotumumab-trbw) use at the American Thyroid Association (ATA) 2022.